NCT07848295
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07848295
Title A Study to Assess the Safety and Tolerability of BMS-986527 in Participants With Clear Cell Renal Cell Carcinoma (ccRCC)
Recruitment Not yet recruiting
Gender both
Phase Phase I
Variant Requirements No
Sponsors Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA | NLD | ITA | FRA | ESP | DEU | BEL

Facility Status City State Zip Country Details
Local Institution - 0018 New Haven Connecticut 06510 United States Details
Local Institution - 0022 Basking Ridge New Jersey 07920 United States Details
Local Institution - 0024 New York New York 10027 United States Details
Local Institution - 0017 Cleveland Ohio 44195 United States Details
Local Institution - 0019 Houston Texas 77030 United States Details
Local Institution - 0026 Seattle Washington 98109-1024 United States Details
Local Institution - 0004 Ghent Oost-Vlaanderen 9000 Belgium Details
Local Institution - 0003 Leuven 3000 Belgium Details
Local Institution - 0007 Villejuif Val-de-Marne 94800 France Details
Local Institution - 0014 Marseille 13273 France Details
Local Institution - 0005 Essen North Rhine-Westphalia 45122 Germany Details
Local Institution - 0012 Jena Thuringia 07747 Germany Details
Local Institution - 0010 Rozzano Milano 20089 Italy Details
Local Institution - 0011 Roma 00168 Italy Details
Local Institution - 0008 Amsterdam 1066 CX Netherlands Details
Local Institution - 0020 Madrid 28040 Spain Details
Local Institution - 0002 Madrid 28041 Spain Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field